# Phase 1/1b Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination With Irinotecan in Subjects With Advanced Solid Tumors

> **NCT00298675** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 59 (actual)

## Conditions studied

- Tumors

## Interventions

- **DRUG:** BSI-201 (iniparib)
- **DRUG:** irinotecan

## Key facts

- **NCT ID:** NCT00298675
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2010-07
- **Final completion:** 2011-05
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2012-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00298675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00298675, "Phase 1/1b Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination With Irinotecan in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00298675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*